Optimal Number of Docetaxel Cycles in Castration-Resistant Metastatic Prostate Cancer

In a retrospective study, treatment with eight or more cycles was associated with superior overall survival.

Docetaxel remains an important therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC), despite the approval of many new agents. In a pivotal study that led to approval of docetaxel for mCRPC (N Engl J Med 2004; 351:1502), patients received a median of 9.5 cycles of docetaxel administered every 3 weeks. However, the optimal number of cycles remains undefined.

To determine whether the number of docetaxel cycles is an independent prognostic factor for overall survival (OS), investigators retrospectively analyzed data from the Mainsail trial (Lancet Oncol 2015; 16:417), in which 1059 patients with mCRPC were randomized to receive docetaxel plus prednisone with or without lenalidomide. This study was stopped …

Reviewing Author

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Optimal Number of Docetaxel Cycles in Castration-Resistant Metastatic Prostate Cancer

Topics

Reviewing Author